Literature DB >> 10712632

Reduction of stress-induced analgesia but not of exogenous opioid effects in mice lacking CB1 receptors.

O Valverde1, C Ledent, F Beslot, M Parmentier, B P Roques.   

Abstract

CB1 cannabinoid receptors are widely distributed in the central nervous system where they mediate most of the cannabinoid-induced responses. Here we have evaluated the interactions between the CB1 cannabinoid receptors and the endogenous opioid system by assaying a number of well-characterized opioid responses, e.g. antinociception and stress-mediated effects, on mutant mice in which the CB1 receptor gene was invalidated. The spontaneous responses to various nociceptive stimuli (thermal, mechanical and visceral pain) were not changed in mutant CB1 mice. Furthermore, the absence of the CB1 cannabinoid receptor did not modify the antinociceptive effects induced by different opioid agonists: morphine (preferential mu opioid agonist), D-Pen2-D-Pen5-enkephalin (DPDPE) and deltorphin II (selective delta opioid agonists), and U-50,488H (selective kappa opioid agonist) in the hot-plate and tail-immersion tests. In contrast, the stress-induced opioid mediated responses were modified in CB1 mutants. Indeed, these mutants did not exhibit antinociception following a forced swim in water at 34 degrees C and presented a decrease in the immobility induced by the previous exposure to electric footshock. However, the antinociception induced by a forced swim in water at 10 degrees C was preserved in CB1 mutants. These results indicate that CB1 receptors are not involved in the antinociceptive responses to exogenous opioids, but that a physiological interaction between the opioid and cannabinoid systems is necessary to allow the development of opioid-mediated responses to stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10712632     DOI: 10.1046/j.1460-9568.2000.00929.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  22 in total

1.  Functional interaction between opioid and cannabinoid receptors in drug self-administration.

Authors:  M Navarro; M R Carrera; W Fratta; O Valverde; G Cossu; L Fattore; J A Chowen; R Gomez; I del Arco; M A Villanua; R Maldonado; G F Koob; F Rodriguez de Fonseca
Journal:  J Neurosci       Date:  2001-07-15       Impact factor: 6.167

Review 2.  The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.

Authors:  Roger G Pertwee
Journal:  AAPS J       Date:  2005-10-24       Impact factor: 4.009

3.  [Cannabinoids in pain medicine].

Authors:  M Karst
Journal:  Schmerz       Date:  2018-10       Impact factor: 1.107

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 5.  Neurobiological Interactions Between Stress and the Endocannabinoid System.

Authors:  Maria Morena; Sachin Patel; Jaideep S Bains; Matthew N Hill
Journal:  Neuropsychopharmacology       Date:  2015-06-12       Impact factor: 7.853

6.  The NK1 receptor is essential for the full expression of noxious inhibitory controls in the mouse.

Authors:  H Bester; C De Felipe ; S P Hunt
Journal:  J Neurosci       Date:  2001-02-01       Impact factor: 6.167

Review 7.  The cannabinoid system and pain.

Authors:  Stephen G Woodhams; Victoria Chapman; David P Finn; Andrea G Hohmann; Volker Neugebauer
Journal:  Neuropharmacology       Date:  2017-06-15       Impact factor: 5.250

Review 8.  Cannabinoids: Current and Future Options to Treat Chronic and Chemotherapy-Induced Neuropathic Pain.

Authors:  Henry L Blanton; Jennifer Brelsfoard; Nathan DeTurk; Kevin Pruitt; Madhusudhanan Narasimhan; Daniel J Morgan; Josée Guindon
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

Review 9.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 10.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.